Skip to main content

Table 1 Characteristics of the included trials in this meta-analysis

From: Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis

Author

Year

Geographic Locale

Study Design

Regimen

Sample size

Duration, weeks

Chen [15]

2017

China,Sichuan province

RCT

TDF:300 mg/d; LAM:100 mg/d

100

48

Chen [16]

2013

China,Jiangsu province

RCT

TDF:300 mg/d; LAM:100 mg/d

60

72

Gao [17]

2016

China,Jilin province

RCT

TDF:300 mg/d; LAM:100 mg/d

70

48

He [18]

2015

China,Guangdong province

RCT

TDF:300 mg/d; LAM:100 mg/d

50

48

Jain [12]

2006

the USA

Retrospective cohort

TDF:300 mg/d; LAM:100 mg/d

25

48

Li [13]

2016

China,multi-centers

Retrospective cohort

TDF:300 mg/d; LAM:100 mg/d

151

48

Liu [19]

2017

China,Shaanxi province

RCT

TDF:300 mg/d; LAM:100 mg/d

120

72

Luo [20]

2016

China,Jiangxi province

RCT

TDF:300 mg/d; LAM:100 mg/d

20

24

Min Zhou [21]

2016

China,Jiangxi province

RCT

TDF:300 mg/d; LAM:100 mg/d

90

48

Wang [14]

2016

China,Guangxi province

RCT

TDF:300 mg/d; LAM:100 mg/d

31

11~ 24

Yan Zhou [22]

2016

China,Henan province

RCT

TDF:300 mg/d; LAM:100 mg/d

110

48

  1. Sample size and duration were expressed in mean